Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics
about
Pharmacokinetic drug interactions in liver disease: An updateCoordinating Role of RXRα in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic ModelingVirtual Experiments Enable Exploring and Challenging Explanatory Mechanisms of Immune-Mediated P450 Down-RegulationAssessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative ColitisIntrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implicationsA clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes.Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism.Inter-individual variation in midazolam clearance in children.Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendiumDrug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.Immunological response as a source to variability in drug metabolism and transport.Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model.Organotypic liver culture models: meeting current challenges in toxicity testing.Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patientsMicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective TherapySudden-onset dystonia in a patient taking asenapine: interaction between ciprofloxacin and asenapine metabolismTherapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.Drug metabolism alterations in nonalcoholic fatty liver diseaseImpact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil.Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are downregulated in a Th2 environment during Schistosoma mansoni infection.Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem.Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions.4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Nuclear receptors in the cross-talk of drug metabolism and inflammation.Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).Management of lipid disorders in patients living with HIV.Systems engineering meets quantitative systems pharmacology: from low-level targets to engaging the host defenses.Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.
P2860
Q26774479-CA5D145A-95A4-40A7-9DA7-539E94FCF4ACQ28551973-C5C4C52B-699E-4CC3-A269-B603D68C2B94Q28552467-C6DB540B-B6AF-42F9-9FA2-21658387ABB0Q28597396-A62C4B1B-85BD-4DEE-B0F7-EA2F8F02AC3CQ33714926-55DF320E-62E8-409B-B706-BBF00FACB543Q34099814-097570F0-A702-4BCC-9D8B-C6CBC101CD24Q34286862-42F40B05-5564-4219-AC3A-1291B150431BQ34857012-52D1E12F-1A8D-4569-9721-4810AA78DD99Q34987988-2247A33B-775A-4D07-98F9-4627342DF662Q35301181-4B6333BB-B528-475E-92F1-9B7EAE5B1C80Q35575682-851A4507-CE1F-43F9-854F-F57C9C02DAFCQ35624602-6924708D-C0D8-45DC-BD33-D4222463E0C4Q35749503-4FFA4A90-3FC6-4B77-BF19-1567EB9E48BAQ35967863-8335247C-8745-49F1-8412-FE40E425B920Q36178225-D5464821-4AED-48EC-9771-E835EFDA5AB0Q36243677-AA341BFA-0967-4E6F-91FC-4A60ED403AA1Q36618667-900A41CF-B9DF-4E19-93A8-CD4BDAD6FD35Q36927325-0A3F54E1-A564-47FF-8506-8B0889BFD1D1Q37030744-7F9EB54D-5772-417D-A27F-2AE6934CE144Q37120909-A6626EA3-6739-4119-9F8E-C44DC20538E0Q37335874-434B33DD-CE35-44CD-A22C-0EC36720FABDQ37422679-2A822019-DE68-4338-AE5F-523D9588D75CQ37592262-4E7F7F18-6DBF-4871-A235-FA3EC0693BE6Q37600383-699C8B2D-1EB4-4E9B-B57C-38EA88E2AB33Q37679511-1A9CFB03-4A00-4720-A7C7-24724B14EBA2Q37700667-09A256DC-B2D0-4814-A5F6-84C8FC9E55FFQ37770251-7D66B228-D136-4BF3-B12B-0B001EB6B2F1Q37964754-D9FFE7A9-B380-4B9C-8F7A-D64389B83312Q38072598-BCB68961-7A5F-4F3D-B798-D1077A2F2C5EQ38074993-3DFA8397-00FB-4EB2-9A55-761BD3C1CEADQ38103883-39735CA4-5F07-48AE-B0E9-37EE9296993CQ38121621-8971EDB5-339E-4609-BF9D-DAA6643DFB17Q38128342-42C08E9B-FF6B-4048-A0AC-B06734D21E03Q38138158-2CBF4E8B-B99F-4A24-AEFF-808E37634F45Q38225574-AB88B424-C507-486C-8062-2F34AFE1C6C4Q38253565-9526880D-7215-4F3D-BBE1-B52AF4073868Q38344129-181967C6-429C-4DCB-A5A1-345C43078947Q38380621-868FD0BC-0DE1-44EB-AD38-DD8D9A7E56B6Q38390695-4BC97D48-F476-4D27-8C59-6E24DB418887Q38627857-EB872CAD-9FA5-4BB2-B99A-2DE77FD85422
P2860
Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Impact of infectious and infla ...... etabolism and pharmacokinetics
@ast
Impact of infectious and infla ...... etabolism and pharmacokinetics
@en
type
label
Impact of infectious and infla ...... etabolism and pharmacokinetics
@ast
Impact of infectious and infla ...... etabolism and pharmacokinetics
@en
prefLabel
Impact of infectious and infla ...... etabolism and pharmacokinetics
@ast
Impact of infectious and infla ...... etabolism and pharmacokinetics
@en
P2860
P356
P1476
Impact of infectious and infla ...... etabolism and pharmacokinetics
@en
P2093
E T Morgan
P2860
P304
P356
10.1038/CLPT.2008.302
P407
P577
2009-02-11T00:00:00Z